Clinical trial
A Phase III, Randomised, Double-Blind, Placebo-Controlled Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT02057666 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomised, Double-Blind, Placebo-Controlled Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
- Lead sponsor
- Ipsen
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- January 31, 2014
- Completion date
- May 31, 2015
- Enrollment
- 146 (actual)
- Sites
- 36
Conditions
As the registry lists them; a condition with its own page is linked.